Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

BRCA1/BRCA2 founder mutations and cancer risks: impact in the western Danish population

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Risk of multiple colorectal cancer development depends on age and subgroup in individuals with hereditary predisposition

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Unsolicited information letters to increase awareness of Lynch syndrome and familial colorectal cancer: reactions and attitudes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Expanding the genotype-phenotype spectrum in hereditary colorectal cancer by gene panel testing

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. No evidence of increased breast cancer risk for proven noncarriers from BRCA1 and BRCA2 families

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Germline TERT promoter mutations are rare in familial melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Broadening risk profile in familial colorectal cancer type X; increased risk for five cancer types in the national Danish cohort

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A rare missense variant in APC interrupts splicing and causes AFAP in two Danish families

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Mutations in the BRCA1 and BRCA2 genes significantly contribute to hereditary breast cancer and ovarian cancer, but the phenotypic effect from different mutations is insufficiently recognized. We used a western Danish clinic-based cohort of 299 BRCA families to study the female cancer risk in mutation carriers and their untested first-degree relatives. Founder mutations were characterized and the risk of cancer was assessed in relation to the specific mutations. In BRCA1, the cumulative cancer risk at age 70 was 35 % for breast cancer and 29 % for ovarian cancer. In BRCA2, the cumulative risk was 44 % for breast cancer and 15 % for ovarian cancer. We identified 47 distinct BRCA1 mutations and 48 distinct mutations in BRCA2. Among these, 8 founder mutations [BRCA1 c.81-?_4986+?del, c.3319G>T (p.Glu1107*), c.3874delT and c.5213G>A (p.Gly1738Glu) and BRCA2 c.6373delA, c.7008-1G>A, c.7617+1G>A and c.8474delC] were found to account for 23 % of the BRCA1 mutations and for 32 % of the BRCA2 mutations. The BRCA1 mutation c.3319G>T was, compared to other BRCA1 mutations, associated with a higher risk for ovarian cancer. In conclusion, founder mutations in BRCA1 and BRCA2 contribute to up to one-third of the families in western Denmark and among these the BRCA1 c.3319G>T mutation is potentially linked to an increased risk of ovarian cancer.

OriginalsprogEngelsk
TidsskriftFamilial Cancer
Vol/bind15
Udgave nummer4
Sider (fra-til)407-12
ISSN1389-9600
DOI
StatusUdgivet - okt. 2016

ID: 46179591